

Publications dinox

IJM.Duijkers, C Klipping, T Rautenberg, BS.Schug, PS.Kochhar, H Osterwald, M Oettel. Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel. *Contraception* 2022;110:6-15

K Erb-Zohar, H Sourgens, K Breithaupt-Groegler, C Klipping. Unintended drug exposure during pregnancy in clinical trials – a survey in early drug development. *International Journal of Clinical Pharmacology and Therapeutics* 2021;59:26-30

I Duijkers, C Klipping, V Kinet, M Jost, A Bastidas, J-M Foidart. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. *Contraception* 2021;103:386-393

M-H Schultze-Mosgau, B Schütt, C Draeger, M Casjens, S Löwen, T Zimmermann, B Rohde. The effects of Vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive. *Br J Clin Pharmacol* 2021;87:925-936

C Klipping, I Duijkers, M Mawet, C Maillard, A Bastidas, M Jost, J-M Foidart. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. *Contraception* 2021;103:213-221

J Douxfils, C Klipping, I Duijkers, M Jost, J Rosing, J-M Foidart. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. *Contraception* 2020,102:396-402.

I.J.M. Duijkers, C. Klipping, C. Draeger, B.S. Schug, A. Dax, M. Friedrich, K. Nickisch. Ovulation inhibition with a new vaginal ring containing trimegestone. *Contraception* 2020;102:237-242.

C Banh, T Rautenberg, I Duijkers, P Borenzstein, C Monteil, D Levy-Gompel, C Klipping, B Scherrer, A Glasier. The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg. *Contraception* 2020;102:145-151

MC Fox, C Klipping, AM Nguyen, TL Frenkl, SM Cruz, Y Wang, T Korver. A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing norgestrel acetate or etonogestrel and 17 β -estradiol in the treatment of women with primary dysmenorrhea, *Contraception* 2019;99:125-130

IJM Duijkers, I Klingmann, R Prinz, M Wargenau, S Hrafnisdottir, Th B Magnusdottir, C Klipping. Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo. *Human Reproduction* 2018;33:2131-2140

B. Schütt, M-H. Schultze-Mosgau, C. Draeger, Xinying Chang, S. Löwen, A. Kaiser, B. Rohde: Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women. *J Clin Pharmacol.* 2018 Feb;58(2):228-239

I Duijkers, C Klipping, D Heger-Mahn, GN Fayad, TL Frenkl, SM Cruz, T Korver. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17 β estradiol and the progestagens etonogestrel or norgestrel acetate compared to NuvaRing. *Eur J Contrac Reprod Biol* 2018;23:245-254

K Abd-Elaziz, I Duijkers, L Stöckl, B Dietrich, C Klipping, K Eckert, S Goletz. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator controlled pharmacokinetic and pharmacodynamic trials. *Hum Reprod* 2017;32:1639-1647.

K Abd-Elaziz, I Duijkers, L Stöckl, B Dietrich, C Klipping, K Eckert, S Goletz. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator controlled pharmacokinetic and pharmacodynamic trials. *Hum Reprod* 2017;32:1639-1647.

C Klufft, Y Zimmerman, M Mawet, C Klipping, IJM Duijkers, J Neuteboom, J-M Foidart, H Coelingh Bennink. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. *Contraception* 2017;95:140-7.

MGF Gerrits, H Kramer, R el Galta, G van Beerendonk, R Hanssen, K Abd-Elaziz, C Klipping, I Duijkers, SA Stoch. Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function. *Fertil Steril* 2016;105:1056-1062.

M.-H. Schultze-Mosgau, K.Waellnitz, R. Nave, S. Klein, J. Kraetzschmar, T. Rautenberg, H. Schmitz & B. Rohde. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial, *Hum Reprod.* 2016 Aug;31(8):1713-22

IJM Duijkers, D Heger-Mahn, D Drouin, S Skouby. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. *Contraception* 2016;93:303-309.

K Waellnitz, I Duijkers, C Klipping, T Rautenberg, B Rohde, C Zurth. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl oestradiol and gestodene in healthy, young women. *J Obstet Gynaecol* 2016 Jan;36(1):106-13.

V Brache, L Cochon, IJM Duijkers, DP Levy, N Kapp, C Monteil, JL Abitbol, C Klipping. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. *Hum Reprod* 2015 Dec;30(12):2785-93.

IJ M Duijkers, D Heger-Mahn, D Drouin, S Skouby. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. *Eur J Contr Reprod Health Care* 2015; 20: 419-427.

I.J.M. Duijkers, C. Klipping, Y. Zimmerman, N. Appels, M. Jost, C. Maillard, M. Mawet, J-M. Foidart, H.J.T. Coelingh Bennink. Inhibition of ovulation by administration of estetrol in combination with Drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study. *Eur J Contr Reprod Health Care* 2015; 20; 476-489.

M Mawet, C Maillard, C Klipping, Y Zimmerman, J-M Foidart, HJT Coelingh Bennink. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. *Eur J Contrac Reprod Health Care*, 2015; online: 1–13.

ST Cameron, C Berger, L Michie, C Klipping, K Gemzell-Danielsson. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. *Hum Reprod* 2015;30:1566-72.

D Heger-Mahn, G Pabst, A Dienel, S Schläfke, C Klipping. No interacting influence of Lavender oil preparation Silexan on oral contraception using an ethinylestradiol / levonorgestrel combination. *Drugs RD* 2014;14:265-72

KD Cobey, AP Buunk, TV Pollet, C Klipping, S Craig Roberts. Men perceive their female partners and themselves, as more attractive around ovulation. *Biol Psychol*, 2013;94:513-516.

J Endrikat, S Parke, D Trummer, M Serrani, I Duijkers, C Klipping. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. *Contraception*, 2013;87(2):227-34.

W. Junge, D. Heger-Mahn, Dietmar Trummer, Martin Merz. Investigation of the hemostatic effect of a transdermal patch containing 0,55 mg ethinyl estradiol and 2,1 mg gestodene compared with a monophasic oral contraceptive containing 0,03 mg ethinyl estradiol and 0,15 mg levonorgestrel: an open-label, randomized, cross-over study. *Drugs R D* 2013;13:223-33

Christine Klipping, Ingrid Duijkers, Michel P Fortier, Joachim Marr, Dietmar Trummer, Jörg Elliesen. Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomized, controlled study. *J Fam Planning Reprod Health Care* 38:73-83, 2012

Christine Klipping, Ingrid Duijkers, Michel P Fortier, Joachim Marr, Dietmar Trummer, Jörg Elliesen. Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomized, controlled, multicentre study. *J Fam Planning Reprod Health Care* 38:84-93, 2012

Hartmut Blode, Christine Klipping, Frank Richard, Dietmar Trummer, Beate Rohde, Konstanze Diefenbach. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. *Contraception* 85:178184,2012

Yuzuru Anzai, Doris Heger-Mahn, Ilka Schellschmidt, Joachim Marr: Suppression of ovarian activity with a low-dose 217/ regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women, *Contraception* 2012;86:28-34

Christine Klipping, Ingrid Duijkers, Ageeth Remmers, Thomas Faustmann, Christian Zurth, Stefan Klein, Barbara Schütt. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. *J Clin Pharmacol* 2012 52: 1704

Peter Schnabel, Gabriele S Merki-Feld, Alice Malvy, Ingrid Duijkers, Ellen Mommers, Michiel W. van den Heuvel. Bioequivalence and X-Ray Visibility of a Radiopaque Etonogestrel Implant versus a Non-Radiopaque Implant: A 3-Year, Randomized, Double-Blind Study. *Clinical Drug Investigation*, 2012;32:413-422.

Christine Klipping, Ingrid Duijkers, Susanne Parke, Uwe Mellinger, Marco Serrani, Wolfgang Junge. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label,

randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. *Drugs* 11:159-170, 2011

Leena Anttila, Gloria Bachmann, László Hernádi, Michael Kunz, Joachim Marr, Christine Klipping. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. *Eur J Obstet Gynecol Reprod Biol* 155:180-182, 2011

Ingrid JM Duijkers, Christine Klipping, Paul Grob, Tjeerd Korver. Effects of a monophasic combined oral contraceptive containing norgestrel acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. *European Journal of Contraception and Reproductive Health Care*, 15:314-325, 2010, Epub 2010 Aug 9

Ingrid JM Duijkers, Christine Klipping. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. *Gynaecological Endocrinology* 26: 152-160, 2010. Epub 2009 Sep 15

Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. *Contraception* 78: 16-25, 2008

Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. *Contraception* 78: 218-25, 2008. Epub 2008 Jul 11

Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. *Menopause* 15: 248-255, 2008

E Mommers, WM Kersemaekers, J Elliesen, M Kepers, D Apter, HM Behre, J Beynon, PM Bouloux, A Costantino, H-P Gerbershagen, L Grönlund, D Heger-Mahn, I Huhtaniemi, EL Koldewijn, C Lange, S Lindenberg, MC Merigiola, E Meuleman, PFA Mulders, E Nieschlag, A Perheentupa, A Solomon, L Väisälä, FC Wu, M Zitzmann. Male hormonal contraception: a double-blind, placebo-controlled study *J Clin Endocrinol Metab* 2008;93:2572-80.

R Massai, L Mäkäräinen, A Kuukankorpi, C Klipping, I Duijkers, T Dieben. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. *Human Reproduction* 20:2764-2768, 2005

Christine Klipping, Joachim Marr. Effects of two combined oral contraceptives containing ethinyl estradiol 20 µg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. *Contraception* 71: 409-416, 2005

Ingrid JM Duijkers, Lonneke Engels, Christine Klipping. Length of the menstrual cycle after discontinuation of oral contraceptives. *Gynecological Endocrinology* 20: 74-79, 2005

Tjeerd Korver, Christine Klipping, Doris Heger-Mahn, Ingrid Duijkers, Gonnie van Osta, Thom Dieben. Maintenance of ovulation inhibition with the 75-µg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-h delays in tablet intake. *Contraception*, 71:8-13, 2005

D Heger-Mahn, C Warlimont, T Faustmann, C Gerking, C Klipping. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation

inhibition, acceptability and safety over two cycles in female volunteers. *European Journal of Contraception and Reproductive Health Care*, 9:173-181, 2004

Ingrid JM Duijkers, Christine Klipping, Carole HJ Verhoeven, Thom OM Dieben. Ovarian function with the contraceptive vaginal ring (NuvaRing) or an oral contraceptive: a randomized study. *Human Reproduction*, 19: 2668-2673, 2004

Ingrid JM Duijkers, Carole HJ Verhoeven, Thom OM Dieben, Christine Klipping. Follicular growth during pill or ring treatment depends on the day of ovulation in the pre-treatment cycle. *Human Reproduction*, 19: 2674-2679, 2004

D Heger-Mahn, C Warlimont, T Faustmann, C Gerlinger, C Klipping. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. *The European Journal of Contraception and Reproductive Health Care*, 9: 173-181, 2004

Ingrid JM Duijkers, Leoni A Louwé, Ddid DM Braat, Christine Klipping. One, two or three: how many directions are useful in transvaginal ultrasound measurement of ovarian follicles? *European Journal of Obstetrics and Gynecology*, 117: 60-63, 2004

I Duijkers, S Killick, A Bigrigg, T Dieben. A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. *European Journal of Reproductive Health Care*, 9: 131-140, 2004

Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. *Contraception* 2003;67:173-185

Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf H. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. *J Clin Pharmacol* 2003;43:243-251

Ingrid J.M. Duijkers, Christine Klipping, Peter J. Boerrigter, Christel S.M. Machielsen, Joris J. de Bie and Gerrit Voortman. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. *Human Reproduction* 2002;8:1987-1993

J. Endrikat, C. Klipping, M. Cronin, C.Gerlinger, A. Ruebig, W. Schmidt, B. Duesterberg. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20mg ethinyl estradiol and 100mg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. *Contraception* 2002;65:215-221

J. Endrikat, C. Klipping, C.Gerlinger, A. Ruebig, W.Schmidt, T. Holler, B. Duesterberg. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 mg ethinyl estradiol and 75 mg gestodene and a 21-day regimen with 30 mg ethinyl estradiol and 75 mg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. *Contraception* 2001;64:235-241

Van Hoof HJ, de Sevaux RG, van Baelen H, Swinkels LM, Klipping C, Ross HA, Sweep CG. Relationship between free and total 1,25-dihydroxyvitamin D in condition of modified binding. *Eur J Endocrinol* 2001;144:391-396

Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. *Fertility and Sterility*, 75: 316-323, 2001

Duijkers IJM, Klipping C. Ultrasonographic assessment of endocervix and cervical mucus in ovulatory menstrual cycles. *Eur J Obstet Gynecol Reprod Biol*, 93: 13-17, 2000

Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Niebch G, Derendorf H. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. *Clin Pharmacol Ther* 2000;68:617-625

Oral Contraceptive and Hemostasis Study Group. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables. *Contraception* 1999;59:345-355

Van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluff C. A comparative study of the effects of gestodene 60 µg/ethinylestradiol 15 µg and desogestrel 150 µg/ethinylestradiol 20 µg on hemostatic balance, blood lipid levels and carbohydrate metabolism. *Eur J Contracept Reprod Health Care* 1999;4 suppl 2:27-35

Duijkers IJM, Klipping C, Willemsen WNP, Krone D, Schneider E, Niebch G, Hermann R. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist cetrorelix in healthy female volunteers. *Human Reproduction* 1998;13: 2392-2398

C. Klipping and D. Heger-Mahn. Discussion on early clinical drug development in the target population with respect to the field of reproductive endocrinology. *Int J Clin Pharm* 1998;36:591-593

IJM Duijkers, C Klipping, TMT Mulders, HJ Out, HJT Coelingh Bennink, HM Vemer. Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations. *Human Reproduction* 1997;12: 2379-2384

K Breithaupt-Grögler, D Heger-Mahn, C Klipping, R Butzer, I Duijkers, D Geyer, R Hermann, C Hinze, M Mahler, M Seibert-Grafe, K Westermann. Klinische Arzneimittelprüfung an Frauen. Überlegungen zum Thema Schwangerschaftsverhütung. *Deutsches Ärzteblatt* 1997;94: A-991-993

Hermann R, Heger-Mahn D, Mahler M, Seibert-Grafe M, Klipping C, Breithaupt Grögler K, de Mey C. Adverse events and discomfort in studies on healthy subjects: the volunteer's perspective. *Eur J Clin Pharmacol* 1997;53:207-214